Jeff Raphael founded OmniScope Partners with the aim of leveraging his unique combination of experiences in industry and across Wall Street to help guide emerging life sciences enterprises through key inflection points as they seek to advance life-saving technologies and return value to their investors.

Prior to founding OmniScope Partners, Jeff was a Managing Director at Evercore where he was part of the Corporate Advisory practice and the senior leadership team in the firm's Menlo Park office. Prior to joining Evercore, Jeff held senior roles at Piper Sandler and Jefferies where he led transaction execution in healthcare, specifically focusing on innovation leaders across the biopharma, life sciences and heath tech sectors. Prior to this, Jeff was with DaVita Healthcare Partners leading finance and growth initiatives for operations in Washington DC, Maryland and northern Virginia. In this capacity, Jeff also supported the company's Corporate Development team in evaluating potential acquisition targets and developing growth strategies at the local level. Jeff began his career in New York as an investment banking analyst at Credit Suisse.

Jeff holds a BA from the University of Maryland with concentrations in economics and sociology.

Dr. Renee Williams is the Founder & Managing Partner for Williams Biotech Consulting, an independent consulting firm offering business development and strategic advisory services in partnership with OmniScope Partners. Dr. Williams is an expert in genetic medicines and non-viral delivery and brings deep experience as both a scientist and business professional, working across academic research, strategy consulting and big pharma settings in various capacities over the last 10+ years.

Prior to work with OmniScope Partners, Dr. Williams was a Vice President at Eli Lilly where she worked as part of the company's broader business development apparatus to support an external strategy around genetic medicines. In this capacity, Dr. Williams successfully sourced and closed 30+ deals across 9 modalities, 6 therapeutic areas and global territories throughout the U.S., Europe and APAC. Prior to joining Eli Lily, Dr. Williams held multiple roles at Janssen spanning lab science, business strategy and operations. Dr. Williams spent the earlier part of her career as a part-time lecturer and postdoctoral scholar at the University of California, San Diego.

Dr. Williams is an independent board director for Paris-based AGS Therapeutics and an advisory board member for Berlin-based Silica Corpora. She has been featured in several research publications, is the lead inventor on a patent, holds a PhD from the University of California, Riverside in Chemistry and a dual MBA from SC Johnson School of Management at Cornell University and Smith School of Business at Queen's University.